In Silico Study of Eugenol Derivatives as Potential Breast Anticancer Agents Targeting Estrogen Receptor Alpha (ER-α)

Authors

  • Ardelia Mufarrihati Author
  • Dinda Neswita Syafarilla Aryni Author
  • Diah Miftahul Aini Author
  • Muhammad Fikri Author
  • Emmy Yuanita Author

DOI:

https://doi.org/10.15294/ijcs.v15i3.57909

Keywords:

eugenol, in silico, molecular docking, ER-α , anticancer

Abstract

Breast cancer is one of the leading causes of cancer-related mortality, with Estrogen Receptor alpha (ER-α) playing a critical role in ER-positive breast cancer. Resistance to endocrine therapies, such as tamoxifen, has encouraged the development of alternative agents targeting ER-α. Eugenol, a natural phenylpropanoid compound, has demonstrated anticancer activity, and structural modification of eugenol may enhance its binding affinity and therapeutic effectiveness. This study aimed to evaluate the interaction of quinoline-substituted eugenol derivatives with ER-α (PDB ID: 5W9D) using an in silico molecular docking approach. The docking results showed that all tested compounds exhibited better binding affinities than the native ligand. Among them, candidate compound (3) showed the lowest binding affinity value of −7.8 kcal/mol and hydrophobic interactions with key active-site residues such as Glu17, Ile20, Ile80, Trp87, and Arg88, indicating high complex stability. These results suggest that quinoline-based eugenol derivatives, particularly candidate compound (3), have potential as ER-α inhibitors and promising lead compounds for breast cancer therapy.

Downloads

Download data is not yet available.

Downloads

Published

13-11-2026

How to Cite

In Silico Study of Eugenol Derivatives as Potential Breast Anticancer Agents Targeting Estrogen Receptor Alpha (ER-α). (2026). Indonesian Journal of Chemical Science, 15(3), 104-115. https://doi.org/10.15294/ijcs.v15i3.57909

Similar Articles

11-20 of 76

You may also start an advanced similarity search for this article.